<?xml version="1.0" encoding="UTF-8"?>
<p>DNA vaccines and recombinant vector DNA vaccines have been studied in EV-A71 vaccine development. Several research groups have designed and constructed a DNA vaccine against EV-A71 infection using its viral capsid protein (VP1) gene in order to verify the functionality of this vaccine 
 <italic>in vitro</italic> and/or 
 <italic>in vivo</italic>
 <xref rid="B48" ref-type="bibr">
  <sup>48</sup>
 </xref>
 <sup>-</sup>
 <xref rid="B50" ref-type="bibr">
  <sup>50</sup>
 </xref> . One study showed that vaccination with an EV-A71 DNA vaccine could elicit VP1-specific IgG titers and neutralizing antibodies against EV-A71, although it resulted only in low levels of antigenicity 
 <xref rid="B48" ref-type="bibr">
  <sup>48</sup>
 </xref> . Another study by Chiu 
 <italic>et al</italic> . 
 <xref rid="B49" ref-type="bibr">
  <sup>49</sup>
 </xref> investigated the potential use of attenuated 
 <italic>Salmonella enterica</italic> serovar Typhimurium strains to express and deliver VP1 of EV-A71 as a vaccine to prevent EV-A71 infections in mice. They showed that offspring born to female mice immunized with 
 <italic>Salmonella</italic> -based VP1 vaccine had higher survival rates (50-60%) than offspring of unvaccinated control mice (0%) 
 <xref rid="B49" ref-type="bibr">
  <sup>49</sup>
 </xref> . Another study indicated that recombinant adenoviruses, expressing EV-A71 P1 and 3CD genes, could elicit production of neutralizing antibodies and protect against EV-A71 infection, both useful characteristics for the prevention of EV-A71 infections 
 <xref rid="B50" ref-type="bibr">
  <sup>50</sup>
 </xref> . Although promising preliminar results have been shown, further investigation on the immunogenicity of this potential EV-A71 DNA vaccine is needed.
</p>
